8-K: BioAffinity Sets 2026 Annual Meeting, Shareholder Deadlines
Annual Meeting Announcement
BioAffinity Technologies, Inc. announced its 2026 Annual Meeting for April 30, 2026, and set a February 14, 2026, deadline for shareholder proposals.
Summary
- The Board of Directors of bioAffinity Technologies, Inc. has set April 30, 2026, as the date for its 2026 Annual Meeting of Stockholders.
- The 2026 Annual Meeting will be held at the company's principal executive offices located at 3300 Nacogdoches Road, Suite 216, San Antonio, TX 78217.
- The company expects to include proposals from its Special Meeting of Stockholders, which was originally convened on December 19, 2025, but adjourned due to a lack of quorum.
- Stockholders wishing to bring business or nominate a director for the 2026 Annual Meeting must provide written notice by February 14, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, procedural announcement regarding the scheduling of an annual meeting and related deadlines, with no immediate positive or negative financial implications.
Risks
- The Special Meeting of Stockholders, originally convened on December 19, 2025, was adjourned without conducting any business due to an insufficient number of shares present in person or by proxy to constitute a quorum, indicating potential challenges in shareholder engagement or participation for future votes.
Future Outlook
The company expects to disclose further details regarding the 2026 Annual Meeting in its definitive proxy statement to be filed with the Securities and Exchange Commission.
Industry Context
StockSavvy.ai notes that this announcement is a standard corporate governance procedure for publicly traded companies, ensuring compliance with regulatory requirements for shareholder meetings. The mention of an adjourned special meeting due to lack of quorum, while not uncommon, could signal a need for enhanced shareholder outreach compared to industry peers who typically achieve quorum more readily.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Scheduling | The Board of Directors established April 30, 2026, as the date for the 2026 Annual Meeting of Stockholders. | 2026-02-04 | Provides clarity to shareholders regarding the timing of the next annual meeting. |
| Shareholder Proposal Deadline | A deadline of February 14, 2026, was set for stockholders to submit written notice for proposed business or director nominations, as per the company's Amended and Restated Bylaws. | 2026-02-04 | Establishes a clear timeline for shareholder participation in the annual meeting agenda. |
| Meeting Adjournment | The Special Meeting of Stockholders, originally on December 19, 2025, was adjourned due to a lack of quorum, with its proposals expected to be included in the 2026 Annual Meeting. | 2025-12-19 | Highlights a past challenge in achieving shareholder participation, potentially indicating a need for improved engagement strategies. |
Stakeholder Impact
- Shareholders: Must be aware of the 2026 Annual Meeting date and the deadline for submitting proposals or nominations. The prior lack of quorum at a Special Meeting may prompt increased attention to participation.
Next Steps
- The company will disclose further details of the 2026 Annual Meeting in its definitive proxy statement to be filed with the SEC.
- Stockholders must provide timely notice by February 14, 2026, for any proposed business or director nominations for the 2026 Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-12-19 | Original date of the Special Meeting of Stockholders, which was subsequently adjourned due to lack of quorum. |
| 2026-02-04 | Date of this Current Report on Form 8-K, announcing the 2026 Annual Meeting date. |
| 2026-02-14 | Deadline for stockholders to provide written notice for proposed business or director nominations for the 2026 Annual Meeting. |
| 2026-04-30 | Date of the Company's 2026 Annual Meeting of Stockholders. |
Recommendation
holdThis filing is a routine corporate governance update regarding the scheduling of the annual meeting and shareholder proposal deadlines. It provides no new material financial or operational information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors.
Keywords
bioAffinity Technologies, Annual Meeting, Stockholders Meeting, Corporate Governance, Shareholder Proposals, Proxy Statement, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.